A activity came when pharma giant Pfizer ( PFE ) announced the acquisition of Hospira ..... over the prior-day closing price. Pfizer would pay the 40% premium on top ..... objectives is tough to do. Essentially, Pfizer management believes the market has
Feb 26 (Reuters) - A U.S. Centers for Disease Control and Prevention (CDC) advisory committee on Thursday recommended meningitis B vaccines for people at high risk aged 10 to 25, a population that...
Feb 26 (Reuters) - An advisory committee to the U.S. Centers for Disease Control and Prevention (CDC) has recommended that people aged 10 to 25 at increased risk of meningitis be vaccinated against the bacteria, Pfizer Inc said on Thursday.
PARIS, Feb 20 (Reuters) - Sanofi's new boss Olivier Brandicourt could earn up to 4.2 million euros ($4.8 million) a year at the drugs group and pocket an extra 4 million euros within 12 months as a one-off golden handshake.
expected to enter the market in 2015. Also, Brandicourt brings a strong understanding of pricing pressure as the leader of Pfizer 's primary care business from 2009 to 2012, a time of major pricing pressure for cholesterol drug Lipitor and several
significant potential catalyst for the firm, we believe it faces a challenging environment given the disappointing launch of Pfizer 's Xeljanz. In addition, the broad Phase II program for IDO1 inhibitor INCB24360 continues to progress in combination
on our earnings and cash flow projections for 2015, and we're leaving our $90 fair value estimate in place based on Pfizer 's recent announcement that it will purchase the company. We continue to believe Hospira's biosimilars pipeline, the
(Reuters) - Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.
Feb 9 (Reuters) - Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.
that signal as well. Stipp: In stock news, [TICKER: PFE ] Pfizer ( PFE ) announced that it's paying a pretty decent premium ..... our take on that deal? Glaser: Damien Conover, our Pfizer analyst, thinks that it's going to be a good one for